Sell-siders bullish on Moderna COVID-19 vaccine

 

• Staying on script, sell-side analysts are on board with Moderna's (NASDAQ:MRNA) mRNA-1273, expected to receive an FDA emergency use nod this month followed by a thumbs up in Europe next month.
• Jefferies' Michael Yee says antibody levels remain high beyond three months and the trajectory continues to support likely protection against SARS-Cov-2 for about a year, in line with expectations. He sees supply constraints in H1 2021 but believes most Americans who want to be vaccinated should be able to do so by the summer. Investors continue to be concerned about supply issues after Pfizer's (NYSE:PFE) announcement yesterday that supply chain hurdles will constrain 2020 shipments of BNT162b2.
• Piper Sandler analysts expect positive opinions from the FDA panel meeting on the 17th and the meeting in Europe on January 12 by the advisory group CHMP.
• Investors clearly agree. Shares are up 704% this year.
• MRNA is up 1% premarket on light volume.
• Related tickers: (NASDAQ:BNTX) (-1%), (NYSE:JNJ) (+1%), (NASDAQ:AZN) (+1%)
• https://seekingalpha.com/news/3641671-sell-siders-bullish-on-moderna-covidminus-19-vaccine